Skip to main content

Cannabis news worldwide -- Inside Canada's New Cannabis & Hemp Regulations

Inside Canada's New Cannabis & Hemp Regulations

Access to medical cannabis in Canada has been permitted since 1999. The current Canadian framework allowing Canadians access to medical cannabis is found in the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”), which has been in place as of Aug. 24, 2016, and sets out the current legal structure of Canada’s evolving medical cannabis framework. Because legislators and regulators in Canada are currently changing the country’s medical cannabis laws, it is worth examining where the industry stands today.

Adult-Use and Medical Cannabis in Canada

Canada’s proposed adult-use law is designed to “keep cannabis out of the hands of children and youth and keep profits out of the hands of organized crime.” In May 2017, Health Canada committed to streamlining the medical license application process to enable increased production for medical purposes, also ensuring supply meets demand once the adult-use legislation is enacted. As of late 2017, approximately 200 applications for a medical license are close to being issued a license. What these measures would suggest is that Health Canada continues to focus on reducing the scale of the illicit cannabis market and aligning its approach with regulations, “the existing evidence of risks to public health and safety, and its approach to other regulated sectors.”

Health Canada is the Canadian federal department responsible for licensing and overseeing the commercial medical cannabis industry, and registering individuals to produce cannabis for their own medical purposes. Under the licensing process, Health Canada can authorize each Licensed Producer (known as an “LP”) to cultivate, process, sell, import/export and other related activities, and Licensed Dealers to test, transport and deliver cannabis as well as sell to authorized persons, among other related activities.

As part of the election promise to legalize cannabis, the Liberal Party of Canada introduced into the House of Commons “Bill C-45” on April 13, 2017, which, once passed, makes cannabis use legal in Canada and amends other related acts, such as the criminal code and the Controlled Drugs and Substances Act with respect to cannabis. Bill C-45 is currently in the Senate for approval, the final review process prior to a bill receiving Royal Assent and becoming law. The intention of the Canadian federal government is that Bill C-45 receive Royal Assent during the summer of 2018.

According to section 158(1) of the proposed law, a Licensed Producer authorized to cultivate, process and sell cannabis under the ACMPR for medical purposes is deemed to be a licensee issued under section 62 of Bill C-45. This means that ACMPR medical cannabis LPs are also automatically permitted to grow and sell non-medical cannabis. In addition, the regulations for the adult-use industry — released in November 2017 — outline a framework to permit smaller scale licenses, known as micro licenses to engage in micro-cultivation, micro-processing, and sales, promoting a craft cannabis market in Canada. Until the final regulations are published, the application process for micro licenses remains unclear, as does the definition of “micro,” with possible defining considerations including canopy space, plant count, square footage of grow space, gross revenue and so on.

Under the proposed regulations, each of Canada’s 13 provinces and territories are tasked with implementing a distribution and retail sale framework for the sale of cannabis for non-medical purposes. If a province or territory has not created the above framework by the time the bill is enacted, the regulations will allow the Canadian federal government to implement a mail order system in that province or territory.

Hemp in Canada

There are many varieties of the cannabis plant, and hemp, also called industrial hemp, refers to the varieties of Cannabis sativa L. which typically contains less than 1 percent tetrahydrocannabinol (or THC). Although cannabis is a controlled substance in Canada, there are exceptions, including medical cannabis use and industrial hemp, under the Industrial Hemp Regulations (IHR).

The IHR defines Industrial Hemp as “the plants and plant parts of the genera Cannabis, the leaves and flowering heads of which do not contain more than 0.3 percent THC”, and permits certain activities with respect to hemp for commercial purposes through a licensing system. However, current licenses granted under the IHR expire in the calendar year they are issued.

Under Canada’s proposed new cannabis regulations, every license or authorization issued under the IHR prior to the commencement date of Bill C-45 will be deemed to be a license issued under Section 62 of that law. According to the draft regulations, non-viable seed, mature stalk without any leaf, flower, seed or branch fall outside the scope of the adult-use law, and therefore no license would be required for processing or sale, or for the sale of any derivatives of seed and grain containing 10 micrograms/grams THC.

The IHR applies to the importation, exportation and possession of industrial hemp and its production, sale, provision, transport, sending or delivering. The IHR does not apply to the importation, exportation, sale or provision of whole industrial hemp plants, including sprouts, or the leaves, flowers or bracts of those plants, or their derivatives, or any derivative of seed, viable or non-viable seed, or products from that derivative, if the derivative or product contain more than 10 micrograms/gram THC.

Both Canada’s Controlled Substances Act and the IHR do not apply to the importation, exportation or wholesale sale of a derivative of seed, viable grain or non-viable cannabis seed, or a product made from that derivative, if not made from whole industrial plants (including sprouts, leaves, flowers or bracts of those plants). The laws also do not apply to an industrial hemp derivative or product that has 10 micrograms/gram THC or less, labelled as such, and accompanied by a certificate of THC from a trusted laboratory. An example of such a derivative or product that the Controlled Substances Act or IHR would not apply to may be hemp seed oil and flour with less 10 micrograms/gram THC or less.

Under the proposed regulations for Canada’s adult-use cannabis market, industrial hemp would be defined as “cannabis plants whose leaves and flowering heads do not contain more than 0.3 percent THC,” and similar to the micro-license framework for non-medical cannabis, industrial hemp licenses will be permitted to possess, transport, research and sell industrial hemp leaves, flowers and branches (or the whole plant).

The regulations will also modify existing physical security requirements for industrial hemp licenses and begin treating industrial hemp storage as any other agricultural product. This includes a proposal to remove a current IHR requirement that industrial hemp be stored in a locked container or location, or premises to which only authorized persons have access.

Currently, industrial hemp licences authorize the cultivation of industrial hemp from approved varieties from pedigreed seeds, those that have been confirmed to consistently produce less than 0.3 percent or less THC. The benefit of using approved pedigreed seeds is that these licensees would be permitted to bypass the lab THC testing requirement. Lab testing would remain mandatory for those Industrial Hemp licensees under the new regulations who do not use pre-approved pedigreed seeds to confirm THC content.

Canadian Capital Markets and Cannabis

On October 16, 2017, the Canadian Securities Administrators released a bulletin which recognized the illegal status of cannabis at the federal level in the U.S., the conflict between the U.S. federal and state cannabis laws and the general U.S. policy based on the Cole Memorandum. This bulletin is currently under review by the CSA in light of U.S. Attorney General Jeff Sessions rescinding of the Cole Memorandum on Jan. 4 of this year.

“We remind investors that the political and regulatory circumstances surrounding the treatment of U.S. marijuana-related activities are uncertain,” the bulletin read. “In the event that U.S. federal law against marijuana is enforced, there could be material consequences for any issuer with U.S. marijuana- related activities, including prosecution and asset seizure.”

The CSA Staff Notice deferred to Canadian exchanges whether to list or maintain listings of issuers with exposure to the U.S. cannabis industry. The approach taken in Canada by the three major equity changes — the TSX, the TSXV and the CSE — differ. With the TSX and the TSXV, issuers with exposure to the U.S. cannabis industry are deemed to be non-compliant with listing requirements. However, the Canadian Securities Exchange (the CSE) permits issuers to list and maintain their listings with U.S. cannabis-related activities, provided they comply with the U.S. state law in which they operate and meet the risk disclosure requirements under Canadian securities law as highlighted in the CSA Staff Notice.

On Jan. 12, the CSA issued a press release indicating it is “considering whether our disclosure-based approach for issuers with U.S. marijuana-related activities remains appropriate in light of the rescission of the Cole Memorandum.” On February 8, 2018, the CSA concluded “that a disclosure-based approach remains appropriate in the current circumstances,” meaning that their policy would not change.

Exporting Canadian Cannabis

Under the Canada’s medical marijuana laws, an LP can obtain authorization from Health Canada to export cannabis internationally. Until recently, when countries such as Australia and Colombia relaxed rules to allow for the exportation of medical cannabis, Canada faced little competition exporting cannabis globally, gaining first mover advantage into emerging markets such as Germany, Australia, Brazil, Chile, Croatia and New Zealand among others.

Though Canada remains one of 185 parties to three United Nations drug control conventions — the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances and the 1988 Convention against the Illicit Trade in Narcotic Drugs and Psychotropic Substances — other countries continue to watch Canada, the first G7 country, refine its medical cannabis framework and implement a federal regulated non-medical cannabis industry as well. Germany, for example, reached an agreement with Canada to import Canadian medical cannabis while looking to also implement a government regulated medical cannabis framework.

Canada stands to be a leader in the world in setting the standard for developing an accountable and reliable regime for cannabis regulation.

Also by Brent Johnson, COO of Hoban Law Group Denver, and Nav Pannu of Bax Securities Law of Toronto.

TELL US, do you understand the Canadian cannabis framework?

Let's block ads! (Why?)



https://cannabisnow.com/inside-canadas-n...gulations/

from potads - All Forums learn more

Popular posts from this blog

This UK-Based Entrepreneur Has Mastered the Art of Entrepreneurship - Entrepreneur

This UK-Based Entrepreneur Has Mastered the Art of Entrepreneurship - Entrepreneur June 20, 2020 5 min read Opinions expressed by Entrepreneur contributors are their own. All businesses hinge on the success of their founders. With their unique blend of innovation and brilliance, successful entrepreneurs can transform their industries by filling a gap in the market. This is what Vithurs (or V, as he likes to be called) did when he entered the digital marketing world and ultimately launched Blessed CBD —one of the fastest growing CBD brands in the UK. His unique skill set, paired with his fearless approach to business and deep knowledge of the cannabis industry, propelled him towards success. Because ultimately, a company is only as successful as its founder. And there’s no arguing Vithurs is a leading name in the UK’s growing cannabis industry. Global reach in digital marketing Born and raised in the UK, Vithurs was just 13 when he delved into Internet marketing f

Martha Stewart launches CBD line in crowded market - CNN

Martha Stewart launches CBD line in crowded market - CNN The hemp-derived, cannabidiol-rich gummies, soft gels and oil drops officially launched on Thursday after more than a year in development. The products are the result of the style maven's partnership with Canopy Growth ( CGC ) , the Canadian cannabis company with a multibillion-dollar backer in US alcohol giant Constellation Brands ( STZ ) . Stewart joined Canopy as an adviser in early 2019 for the express purpose of developing cannabis products for humans and their pets after being introduced to Canopy's founder by her friend Calvin Broadus Jr. -- the rapper and businessman better known as Snoop Dogg. His Leafs by Snoop cannabis brand is produced by Canopy. The initial Martha Stewart CBD products, which range from $34.99 to $44.99, will be sold online at Canopy's e-commerce site . The pet products are expected to debut later this year. "I was surprised to learn that while most people have heard of

The Half-Legal Cannabis Trap - POLITICO

The Half-Legal Cannabis Trap - POLITICO LOS ANGELES — Everything about Kelvin’s job in a neighborhood southwest of downtown seemed like any other assignment, if not a little more exciting. The 40-year-old, who had previously worked as an electrician, had been employed since 2015 by a private security company that contracted him out to guard marijuana dispensaries. In 2019, he was protecting one of the thousand or so cannabis stores in California’s biggest city—part of an industry that has grown less and less underground since 1996, when the state first legalized medical marijuana. Kelvin, who asked not to be identified beyond his middle name to avoid professional retaliation, doesn’t smoke pot, but says the gig felt like the future. He grew up in a time when other Black people he knew in Los Angeles would go to jail for possessing even small amounts of the drug. Now, customers could walk into shops like the one he was guarding, many of which can be identified by green crosses on